It is also useful to remind people that Reckitt Benckiser has sold its China Infant-formula business at a massive loss recently, for $2.2 billion, to a Chinese investment firm.
Nestle has been experiencing precipitous drops in China sales of its infant-formula products citing increasingly fierce competition and drop in birth rate. And the issues are felt by everyone else in the industry as well such as Danone and, of course, A2M. So there is no commercial sense for Nestle to acquire A2M, none whatsoever. Especially taking into account how tight of a control China has on the company.
Takeover Speculation, page-166
-
- There are more pages in this discussion • 254 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.52 |
Change
-0.040(0.61%) |
Mkt cap ! $4.713B | |||
| Open | High | Low | Value | Volume |
| $6.51 | $6.57 | $6.47 | $13.11M | 2.015M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 37866 | $6.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.52 | 6643 | 2 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| A2M (ASX) Chart |